AKR1C3 and acute lymphoblastic leukemia: We hypothesize that AKR1C3 expression can be used as a method to detect minimal residual disease in T and B-ALL patients, and patients with residual/recurrent ALL can potentially benefit from AKR1C3 targeted therapy.